Adagene Inc.

Contributing Author

Recent Articles by Adagene Inc.

Aug-20	Adagene to Participate in Three Upcoming Investor Conferences ADAG GlobeNewswire
Aug-12	Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates ADAG GlobeNewswire
May-12	Adagene to Participate in Two Upcoming Investor Conferences ADAG GlobeNewswire
Apr-17	Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types ADAG GlobeNewswire
Apr-14	Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board ADAG GlobeNewswire
Apr-02	Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs ADAG -13.45% GlobeNewswire
Apr-02	Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) ADAG -13.45% GlobeNewswire
Apr-02	Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response ADAG -13.45% GlobeNewswire
Apr-01	Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update ADAG +17.60% GlobeNewswire
Mar-17	Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA ADAG GlobeNewswire
Feb-17	Adagene to Participate in Two Upcoming Investor Conferences ADAG GlobeNewswire
Jan-23	Adagene Provides Business Update and 2026 Objectives ADAG +22.66% GlobeNewswire
Dec-16	Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) ADAG +13.77% GlobeNewswire
Nov-13	Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody Technology ADAG GlobeNewswire
Oct-31	Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Microsatellite Stable Colorectal Cancer ADAG -7.29% GlobeNewswire
Sep-16	Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate ADAG GlobeNewswire
Sep-05	Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China ADAG GlobeNewswire
Sep-03	Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor ADAG GlobeNewswire
Aug-26	Adagene to Participate in Two Investor Conferences in September ADAG GlobeNewswire
Aug-12	Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates ADAG -16.59% ADAG -13.61% GlobeNewswire
Jul-15	Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA ADAG GlobeNewswire
Jul-08	Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate ADAG GlobeNewswire
Jul-01	Adagene announces up to $25 million strategic investment from Sanofi ADAG -5.13% GlobeNewswire
May-27	Adagene to Present at Jefferies Global Healthcare Conference 2025 ADAG GlobeNewswire
May-22	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting ADAG ADAG +12.00% GlobeNewswire

Adagene Inc.

Recent Articles by Adagene Inc.

Upgrade your Finviz experience